ImCheck Therapeutics
ImCheck Therapeutics60About
What does ImCheck Therapeutics do?
ImCheck Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of immuno-oncology drugs. Their approach targets novel immune checkpoints to modulate the tumor microenvironment and enhance anti-tumor immunity. The company's lead product candidate, IMC-001, is a first-in-class antibody targeting the TIGIT receptor.
What is ImCheck Therapeutics's revenue?
StartupHub estimates ImCheck Therapeutics's annual revenue at $10.8M (range $7.5M to $24.1M, 65% confidence), based on comparable companies in the sector.
What is ImCheck Therapeutics's valuation?
StartupHub estimates ImCheck Therapeutics's effective valuation at $661.2M (range $410.0M to $984.0M, 10% confidence), based on comparable companies in the sector.
How much funding has ImCheck Therapeutics raised?
ImCheck Therapeutics has raised a total of $164M in funding.
Where is ImCheck Therapeutics headquartered?
ImCheck Therapeutics is headquartered in Marseille, France.
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded in 2015.
What industry does ImCheck Therapeutics operate in?
ImCheck Therapeutics operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Immuno-Oncology.
How many employees does ImCheck Therapeutics have?
ImCheck Therapeutics has approximately 47 people on record.
No comments yet. Be the first to share your take.